A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia

Leukemia Research
Mette ØstergaardP Hokland

Abstract

We have developed a real-time quantitative RT-PCR (RQ-PCR) assay for the DEK-CAN fusion transcript, which results from t(6;9)(p23;q34) and is found in about 1% of acute myeloid leukemia (AML) cases. In diagnostic samples from three acute myeloid leukemia patients an RQ-PCR assay sensitivity of 1:396-1:3446 was obtained. In a single patient followed closely for 57 weeks, an increasing DEK-CAN level was detected 40 days before an early hematological relapse. This assay should enable the widespread longitudinal minimal residual disease (MRD) follow-up in this rare subgroup of AML patients, thus adding to our knowledge of its course.

References

Feb 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·D KraemerA Radu

❮ Previous
Next ❯

Citations

Aug 12, 2008·Seminars in Oncology·Sylvie D FreemanDavid Grimwade
Mar 1, 2013·European Journal of Haematology·Trine SilkjaerCharlotte Guldborg Nyvold
Jan 22, 2015·European Journal of Haematology·Hans B OmmenSusanne Schnittger
Nov 26, 2010·Blood·Peter Hokland, Hans Beier Ommen
Nov 15, 2007·Cancer·Wolfgang KernSusanne Schnittger

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.